{"id":"ibi310","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IBI310 functions as a bispecific monoclonal antibody designed to block two immune checkpoints—PD-1 and TIM-3—that are often co-expressed on exhausted T cells in the tumor microenvironment. By simultaneously targeting both pathways, the drug aims to overcome resistance to single-checkpoint inhibition and restore T cell effector function more effectively than monotherapy approaches.","oneSentence":"IBI310 is a bispecific antibody that simultaneously engages PD-1 on T cells and TIM-3 on tumor-infiltrating lymphocytes to enhance anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:19.053Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT07490262","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.","status":"NOT_YET_RECRUITING","sponsor":"Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.","startDate":"2026-03-31","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":680},{"nctId":"NCT04720716","phase":"PHASE3","title":"A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-02-07","conditions":"Hepatocellular Carcinoma","enrollment":344},{"nctId":"NCT07422753","phase":"PHASE2","title":"A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":36},{"nctId":"NCT07410975","phase":"PHASE2","title":"Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2026-01-10","conditions":"NSCLC Stage II, NSCLC Stage III","enrollment":54},{"nctId":"NCT04868760","phase":"PHASE1","title":"A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Healthy Chinese Male Volunteers","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-05-31","conditions":"Healthy Subjects","enrollment":148},{"nctId":"NCT05165407","phase":"PHASE2","title":"Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)","status":"RECRUITING","sponsor":"Peking University","startDate":"2022-07-12","conditions":"Neuroendocrine Neoplasm","enrollment":30},{"nctId":"NCT04258111","phase":"PHASE2","title":"IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2020-08-27","conditions":"Colorectal Cancer","enrollment":4},{"nctId":"NCT06620822","phase":"PHASE2","title":"Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2024-09-30","conditions":"Non Small Cell Lung Cancer","enrollment":296},{"nctId":"NCT04401813","phase":"PHASE1","title":"Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2020-06-16","conditions":"Advanced Hepatocellular Carcinoma","enrollment":97},{"nctId":"NCT06580574","phase":"PHASE2","title":"Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers","status":"RECRUITING","sponsor":"Peking University","startDate":"2024-08-13","conditions":"Gastric Cancer, Colon Cancer, MSI-H","enrollment":38},{"nctId":"NCT05890742","phase":"PHASE3","title":"A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2023-05-25","conditions":"MSI-H","enrollment":360},{"nctId":"NCT04590599","phase":"PHASE2","title":"A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2020-12-08","conditions":"Advanced Cervical Cancer","enrollment":205},{"nctId":"NCT05653180","phase":"PHASE1, PHASE2","title":"IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer","status":"UNKNOWN","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2023-03-10","conditions":"Advanced Biliary Tract Cancer","enrollment":20},{"nctId":"NCT04277663","phase":"PHASE3","title":"The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery","status":"TERMINATED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2020-04-17","conditions":"Acral Melanoma That Has Been Removed by Surgery","enrollment":136},{"nctId":"NCT03545971","phase":"PHASE1","title":"A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2018-09-25","conditions":"Advanced Solid Tumors","enrollment":53},{"nctId":"NCT05118334","phase":"PHASE1","title":"IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-11-12","conditions":"NSCLC (Non-small-cell Lung Cancer)","enrollment":30},{"nctId":"NCT04945421","phase":"PHASE1","title":"IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-07-23","conditions":"NPC","enrollment":30},{"nctId":"NCT05363722","phase":"PHASE1","title":"A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-05","conditions":"Hepatocellular Carcinoma","enrollment":80},{"nctId":"NCT04202601","phase":"PHASE1, PHASE2","title":"Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer","status":"UNKNOWN","sponsor":"Peking University","startDate":"2019-12-13","conditions":"Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CTLA-4"],"phase":"phase_3","status":"active","brandName":"IBI310","genericName":"IBI310","companyName":"Innovent Biologics (Suzhou) Co. Ltd.","companyId":"innovent-biologics-suzhou-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IBI310 is a bispecific antibody that simultaneously engages PD-1 on T cells and TIM-3 on tumor-infiltrating lymphocytes to enhance anti-tumor immune responses. Used for Advanced or metastatic solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":6,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}